Table 4.

Visual improvement according to genotypes at 12-month.

		Baseline BCVA	P value	BCVA improvement at 12month	P value	Adjusted p value
ARMS2 A69S (rs10490924)	TT	0.42 ± 0.37		−0.12 ± 0.28
	TG	0.49 ± 0.40		−0.20 ± 0.33
	GG	0.30 ± 0.24	0.48	−0.14 ± 0.20	0.34	NA
CFH I62V (rs800292)	GG	0.41 ± 0.37		−0.15 ± 0.26
	GA	0.43 ± 0.41		−0.16 ± 0.32
	AA	0.54 ± 0.45	0.33	−0.25 ± 0.43	0.39	NA
CFH (rs1329428)	CC	0.42 ± 0.37		−0.17 ± 0.27
	CT	0.43 ± 0.38		−0.15 ± 0.30
	TT	0.40 ± 0.45	0.93	−0.14 ± 0.33	0.48	NA
C2-CFB-SKIV2L (rs429608)	AA	0.70 ± 0.42		−0.50 ± 0.14
	AG	0.49 ± 0.44		−0.30 ± 0.37
	GG	0.41 ± 0.36	0.12	−0.13 ± 0.27	1.0 × 10−3	3.0 × 10−3(※)
C3 (rs2241394)	GG	0.7		−0.18
	GC	0.52 ± 0.39		−0.18 ± 0.29
	CC	0.41 ± 0.37	0.11	−0.15 ± 0.29	0.70	NA
CETP (rs3764261)	TT	0.27 ± 0.09		−0.04 ± 0.40
	TG	0.39 ± 0.34		−0.18 ± 0.23
	GG	0.45 ± 0.39	0.081	−0.16 ± 0.30	0.42	NA
ADAMTS9 (rs6795735)	CC	0.33 ± 0.30		−0.14 ± 0.28
	CT	0.35 ± 0.28		−0.09 ± 0.26
	TT	0.45 ± 0.39	0.083	−0.18 ± 0.30	0.057	NA

(※)adjusting for age, gender, baseline BCVA, and AMD subtype.